InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,689.99
(
1.27%
)
Post# of 251707
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

alternatepatel

Send PM Follow Ignore
Followers 12
Posts 1019
Boards Moderated 0
Alias Born 03/24/2013

alternatepatel

Re: DewDiligence post# 212019

Friday, 06/23/2017 9:03:05 AM

Friday, June 23, 2017 9:03:05 AM

Post# of 251707
Leaving the mfg. facility aside, FDA should(/must) have completed rest of the mCopaxone 40 mg review & given a CRL to Momenta much earlier during the 30 month stay (when MNTA was expecting). That would have given $MNTA a chance to explore other fill/finish supplier & launch a lot early than 2018.

This mess created by FDA will cost millions to Momenta. Surprisingly, there's no apparent recourse.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up